Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Korea United PharmXKRX:033270 -1.38%90 FCF Margin % is 15.83% as of Jun. 2026, which is 74% above its 10-year median of 9.11. GuruFocus rates XKRX:033270 with a GF Score™ of 90/100 and a GF Value™ of ₩20,354.74 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 959 Drug Manufacturers companies, Korea United Pharm ranks better than 78.1% on this metric.
The historical data trend for Korea United Pharm's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Korea United Pharm's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Korea United Pharm FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Korea United Pharm's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Korea United Pharm's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Korea United Pharm (XKRX:033270) has a FCF Margin % of 15.83% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Korea United Pharm and its competitors. This is 74% above median its historical median of 9.11. Over the past decade, Korea United Pharm's FCF Margin % has ranged from 0.05 to 15.07. According to the industry distribution chart, Korea United Pharm ranks #210 out of 959 companies in the Drug Manufacturers industry, placing it in the top 21.9%.
Is Korea United Pharm's FCF Margin % too high?
Korea United Pharm's current FCF Margin % of 15.83% is 74% above median its 10-year median of 9.11. Over the past 10 years, this metric has ranged from a low of 0.05 to a high of 15.07. The Drug Manufacturers industry median FCF Margin % is 2.45. Korea United Pharm's value of 15.83% is 546.1% above this industry median. Based on the distribution chart, Korea United Pharm ranks #210 out of 959 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Korea United Pharm has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Korea United Pharm's FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Korea United Pharm ranks #210 out of 959 companies for FCF Margin %. This places Korea United Pharm in the top 22% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 2.45. Korea United Pharm's value of 15.83% is 546.1% above this benchmark. Historically, Korea United Pharm's own FCF Margin % has ranged from 0.05 to 15.07 over the past decade. While the company's 10-year median is 9.11 vs. the industry median of 2.45, Korea United Pharm has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.45, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Korea United Pharm's current FCF Margin % of 15.83% is 546.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Korea United Pharm and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Korea United Pharm's current FCF Margin % is 15.83%, which is 74% above median its own 10-year median of 9.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Korea United Pharm stock overvalued right now?
Based on GuruFocus' analysis, Korea United Pharm (XKRX:033270) is currently considered Modestly Undervalued. The stock's GF Value™ is ₩20,354.74, compared to a current price of ₩17,910.00 — trading 12% below its estimated fair value. The current FCF Margin % is 15.83%, which is 74% above median its 10-year median of 9.11 and 546.1% above the Drug Manufacturers industry median of 2.45. Korea United Pharm's overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Korea United Pharm (XKRX:033270), the current FCF Margin % is 15.83% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Korea United Pharm (XKRX:033270) Overvalued in 2026?
Based on GuruFocus' analysis, Korea United Pharm stock appears to be undervalued.
The current stock price of ₩17,910.00 is trading 12% below its estimated GF Value™ of ₩20,354.74.
GuruFocus considers Korea United Pharm to be Modestly Undervalued.
Key valuation signals for XKRX:033270:
FCF Margin %: 15.83% (74% above median its 10-year median of 9.11)
GF Value™: ₩20,354.74 vs. price of ₩17,910.00 (12% below fair value)
Industry Position: 546.1% above the Drug Manufacturers median (#210 of 959)
No single metric tells the full story. See the XKRX:033270 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Korea United Pharm Inc is a South Korea based company engages in the manufacture and distribution of pharmaceuticals and healthcare products. It offers incrementally modified drug, anti-cancer, prescription, and OTC products.
90GF Score
Get the complete analysis for XKRX:033270
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:033270 has been successfully added to your 
